This excerpt taken from the SNY 6-K filed Jul 31, 2008.
D.1.1.2. Net sales by geographic region
In Europe, after a slight fall in the first quarter, sales rose by 1.0% in the second quarter (on a comparable basis), largely because the rate of decline in German sales slowed. Overall, first-half net sales rose by 0.1% (on a comparable basis). The impact of Eloxatine® generics pared approximately 1.4% off growth for the first half (on a comparable basis).
In the United States, sales rose by 1.5% in the first half (on a comparable basis), boosted by dynamic performances from Lantus (+30.7%), Taxotere (+14.9%), and vaccines (+15.7%). Excluding the impact of generics of Ambien® IR, first-half sales growth would have reached 10.7% on a comparable basis.
Net sales in the Other countries region rose by 10.6% on a comparable basis in the first half of 2008.